

> Microbiology of Pneumonia


# PNEUMONIA

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Microbiology of Pneumonia</b></p></td></tr><tr><td><p><b>臨床Setting</b></p></td><td><p><b>原因</b></p></td></tr><tr><td><p><b>Community- acquired (CAP)</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>4;37</span><span>1</span><span>:</span><span>1</span><span>6</span><span>1</span><span>9 &amp; 373:4</span><span>1</span><span>5;</span> <span><i>Lancet</i></span> <span>20</span><span>1</span><span>5;386:</span><span>1</span><span>097)</span></p></td><td><p><i>No pathogen identified in 50–60%</i>, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in &lt;5%</p><p>Viruses: influenza, RSV, hMPV, rhinovirus (unknown significance), parainfluenza virus, coronavirus</p><p><i>S. pneumoniae</i> (most common bacterial cause)</p><p><i>S. aureus</i> (esp. postinfluenza)</p><p><i>Mycoplasma</i>, <i>Chlamydia</i> (esp. in young &amp; healthy)</p><p><i>H. influenzae</i>, <i>M. catarrhalis</i> (esp. in COPD)</p><p><i>Legionella</i> (esp. in elderly, smokers, ↓ immunity, TNF inhibitors)</p><p><i>Klebsiella</i> &amp; other GNR (esp. in alcoholics &amp; aspiration)</p></td></tr><tr><td><p><b>Hospital-acquired or ventilator-assoc. (HAP/VAP)</b></p></td><td><p><i>S. aureus</i>, <i>Pseudo.</i>, <i>Klebsiella</i>, <i>E. coli, Enterobacter</i>, <i>Acinetobacter, Stenotrophomonas.</i> IV 抗生素 within 90 d RF for MDR.</p><p>Viral~ 20% cases <span>(</span><span><i>Chest</i></span> <span>20</span><span>1</span><span>7;</span> <span>1</span><span>54:</span><span>1</span><span>)</span></p></td></tr><tr><td><p><b>Immunosuppressed</b></p></td><td><p><i>Above</i> + PCP, fungi, <i>Nocardia</i>, non-TB mycobacteria (NTM), CMV</p></td></tr><tr><td><p><b>Aspiration</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:65</span><span>1</span><span>)</span></p></td><td><p><i>Chemical pneumonitis</i> due to aspiration of gastric contents</p><p><i>Bacterial pneumonia</i> ≥24–72 h after aspiration event outPt: oral flora (strep, <i>S. aureus</i>, anaerobes) inPt or chronically ill: GNR (<i>Pseudomonas</i>) and <i>S. aureus</i></p></td></tr></tbody></table>

臨床表現

• Presenting features are variable and depend upon several host factors (esp. age)

• Classically: fever, cough with purulent sputum, consolidation on CXR

• Atypical pathogens (_Legionella, Mycoplasma, Chlamydia_, virus): historically classified as “atypical” b/c they failed to grow on routine cx. Presentation varies from insidious to acute; imaging features vary from interstitial infiltrates to tree-in-bud opacities, to dense consolid.

• 臨床and imaging features do NOT distinguish “typical” from “atypical”

• Aspiration pneumonitis/PNA: can be infectious or non-infectious; may 表現為 acute inflammatory syndrome (fever, ↑ WBC, etc.) or insidious course

• HAP/VAP: develops within 48 h after admission or mechanical ventilation, respectively

Diagnostic studies

• **Sputum Gram stain/Cx:** reliable if high quality (ie, sputum not spit; <10 squamous cells/lpf) & if PNA should be purulent (>25 PMNs/lpf). Yield ↓ >10 h after 抗生素 (_CID_ 2014;58:1782).

• Blood cultures (_before antibiotics!_): ⊕ in ~10% of inPts, depending on pathogen

• **Procalcitonin:** ↑ in acute bacterial (not viral) PNA. Consider stopping 抗生素 if levels <0.25 ng/ml (<0.5 ng/ml in ICU 病人) or ↓ ≥80% from peak. ↓ 抗生素 exposure by 2–3 d (_Lancet ID_ 2016;16:819 & 2018;18:95). Not validated in immunocompromised hosts. Levels harder to interpret in CKD. False ⊕ in cardiac arrest, shock, surgery.

• **CXR** (PA & lateral; see Radiology inserts) → tap effusions if >5 cm or severe PNA

• Other: **SaO2** or PaO2, arterial pH (if severe), CBC with diff, Chem-20; HIV test (if unknown)

• Other micro based on 臨床suspicion (paired serologies available for most atypicals):

_Mycoplasma:_ PCR of throat or sputum/BAL _before_ first dose 抗生素

_Legionella_ urinary Ag (detects _L. pneumophila_ L1 serotype, 60–70% of 臨床disease)

_S. pneumoniae_ urinary Ag (Se 70%, Sp >90%)

MTb: (induced) sputum AFB stain ×3 q ≥8h (w/ ≥1 early morning specimen). Myco-bacterial cx (_empiric respiratory isolation while pending_); MTb DNA PCR if smear ⊕.

• **Viral testing** (DFA or PCR) on nasopharyngeal swab or sputum

• Bronchoscopy: consider if immunosupp., critically ill, failing to respond, VAP, suspected TB or PCP, or inadequate or ⊖ sputum cx. Some pathogens need specific cx media (eg, _Legionella_ on BCYE).

• Reasons for failure to improve on initial Rx:

Insufficient time: may take ≥72 h to see improvement (fever persists >4 d in ~20%)

Insufficient drug levels for lung penetration (eg, vanco trough <15–20 μg/mL)

Resistant organisms (or superinfxn): eg, MRSA, _Pseudo.;_ consider **bronchoscopy**

Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; **consider CT**

Parapneumonic effusion/empyema/abscess: if CXR ⊖, **consider CT** (dx tap ± chest tube if effusion present, esp. if loculated)

Metastatic infection (eg, endocarditis, meningitis, septic arthritis)

Triage

• **qSOFA** predicts poor outcomes, prolonged ICU stay, and in-hospital mortality if >2 of 3: RR>22, AMS, SBP<100 (_JAMA_ 2016; 315:801)

• **CURB-65:** confusion, BUN >20, RR >30, BP <90/60, age >65 If score 0–1: Rx as outpt; 2: Rx as inpt; >3 consider ICU (_Thorax_ 2013; 58:377)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><a id="page_6-2"></a><p><b>治療</b> <span>(</span><span><i>CID</i></span> <span>2007;44 Suppl:S27;</span> <span><i>JAMA</i></span> <span>20</span><span>1</span><span>6;3</span><span>1</span><span>5:593;</span> <span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:65</span><span>1</span><span>)</span></p></td></tr><tr><td><p><b>Scenario</b></p></td><td><p><b>Regimen</b></p></td><td><p><b>Special Considerations</b></p></td></tr><tr><td><p><b>CAP (outPt)</b></p></td><td><p>Azithro <i>or</i> doxy</p></td><td><p><i>Avoid</i> azithro/doxycycline if &gt;25% resist- ance locally. Use FQ OR B-lactam + azithro/doxy.</p></td></tr><tr><td><p><b>CAP (ward)</b></p></td><td><p>Resp FQ <i>or</i> [3<sup>rd</sup>-gen ceph + azithro]</p></td><td><p>Doxycycline can replace azithro</p><p><b>Omadacycline</b> ≈ FQ <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:5</span><span>1</span><span>7)</span></p></td></tr><tr><td><p><b>CAP (ICU)</b></p></td><td><p>Resp FQ + [3<sup>rd</sup>-gen ceph <i>or</i> amp-sulbactam]</p></td><td><p>Only cover MRSA or Pseudomonas if risk factors. If resp FQ contraindic., use azithro</p></td></tr><tr><td><p><b>HCAP (incl. VAP)</b></p></td><td><p>[Pip-tazo <i>or</i> cefepime <i>or</i> carbapen.] + [vanco or linezolid]</p></td><td><p>May add resp FQ (or azithro) when concerned re: atypicals</p></td></tr><tr><td><p><b>Aspiration</b></p></td><td colspan="2"><p>Treat if 異常 CXR (or if need to be intubated or develops septic shock)</p><p>Amox-clav, amp-sulbactam, FQ, carbapenem</p><p>If hosp-acquired and concern for multidrug-resistant pathogens: [pip-tazo, cefepime, or carbapenem] + [AG or colistin]</p></td></tr></tbody></table>

• Avoid quinolones if suspect TB

• Steroids: not standard practice, but appear to ↓ mortality, mech vent, & ARDS (_Cochrane_ 2017;12:CD007720). Consider in severe CAP (FiO2 >0.5 + ≥1 of: pH<7.3; lactate >4; CRP >150). _Avoid_ in suspected or known influenza. Dosing: pred 50 mg PO ×7 d or methylpred 0.5 mg/kg IV BID ×5 d.

• Duration: for CAP, 5 d if stable & afebrile for 48–72 h; for HAP/VAP, 8 d (_CID_ 2017; 65:8)

• When possible, de-escalate 抗生素 based on sensitivities

Prognosis

• For low-risk 病人, can discharge immediately after switching to PO 抗生素 (_CID_ 2007;44:S27)

• CXR resolves in most by 6 wk; consider f/u to 排除 underlying malig (esp. if >50 y or smoker)

Prevention

• All persons >65: give PCV13 vaccine followed by PPSV23 vaccine 1 y later. If PPSV23 already received, give PCV13.

• Age 19–64 with CHF/CMP, lung disease (including asthma), cirrhosis, DM, EtOH, or smoker: give PPSV23.

• Any age with immunocomp., CSF leak, cochlear implant, asplenia: give PCV13 followed by PPSV23 8 wks later.

• Smoking cessation counseling

• VAP precautions: HOB >30°, chlorhexidine rinse; aspiration precautions in high-risk 病人

VIRAL RESPIRATORY INFECTIONS

_URI, bronchitis, bronchiolitis, pneumonia_ (_Lancet_ 2011;377:1264)

Microbiology & 流行病學 ([http://www.cdc.gov/flu/weekly](http://www.cdc.gov/flu/weekly))

• Typical pathogens

short, mild = rhinovirus, coronavirus

longer, more severe or complicated = **influenza**, parainfluenza, respiratory syncytial virus (RSV), adenovirus, metapneumovirus. Can be esp. severe in immunosupp.

Diagnosis

• Sx: fever, cough, myalgias, SOB, wheezing, sore throat, rhinorrhea, malaise, confusion

• Respiratory viral panel on nasal washing or sputum/BAL

• Rapid influenza _nasopharyngeal swab_ preferred to nasal swab (Se 50–70%, Sp >90%)

• RT-PCR for influenza A/B (>95% Se & Sp)

治療 (_NEJM_ 2017;390:697)

• **Influenza:** neuraminidase inhib. (oseltamivir, zanamivir), which are effective vs. A & B (↓ sx by ~1 d), but resistance emerging.

• Oseltamivir dosed 75 mg PO bid × 5 d. Must start within 48 h of sx for low-risk; for critically ill or immunosupp., start as soon as possible even if >48 h.

• Baloxavir superior to oseltamivir in ↓ sx & viral load on 1st day of Rx, but risk of resistance emerges within 病人 (_NEJM_ 2018; 379:913)

• **RSV:** Can consider inhaled ribavirin in immunosupp. (eg, BMT, lung tx); limited adult data

Prevention

• Inactivated **influenza vaccine:** incl. H1N1. Rec for _all_ >6 mo of age and esp. if pregnant, >50 y, immunosupp., or HCW (_MMWR_ 2012;61:613)

• Isolation, droplet precautions for inPts strongly recommended

• Prophylaxis for high-risk contacts of confirmed influenza: oseltamivir 75 mg PO daily × 10 d
